Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 3, 2026.

Results from the Baby-COMET study of avalglucosidase alfa in infantile-onset Pompe disease will support a planned US regulatory submission for a label extension, anticipated in the second half of 2026.

New findings suggest that monoclonal antibody therapy was associated with a 34% lower risk of relapse in patients with AQP4-IgG seropositive NMOSD compared with those who were seronegative.

The professor of neurology at Wake Forest School of Medicine discussed the evolution of sleep medicine education, its relevance across neurologic specialties, and advice for early-career clinicians.

The FDA accepted supplemental applications seek to convert the accelerated approvals of casimersen and golodirsen to traditional approvals in patients with Duchenne muscular dystrophy.

Additional analyses from a phase 2 study evaluating the effects of zervimesine on hallucination in DLB will be presented at the Alzheimer's Association International Conference 2026 .

The FDA will review Capricor Therapeutics' Deramiocel for the treatment of Duchenne muscular dystrophy on July 29, 2026, ahead of the therapy's PDUFA target action date of August 22, 2026.

The ongoing phase 3 RELIEVE trial investigates the efficacy and safety of remibrutinib in patients with generalized myasthenia gravis who are on stable standard-of-care treatment.

A $2.5 million Michael J. Fox Foundation grant is funding 4 new sites for the NEULARK trial assessing NEU-411 as a potential disease-modifying therapy in genetically selected patients with early Parkinson disease.

Here's some of what is coming soon to NeurologyLive® this week.

A recently published 20-year study suggests that preoperative putamen volume on MRI independently can predict motor response to GPi-DBS in patients with dystonia-dyskinesia syndrome secondary to perinatal hypoxic-ischemic encephalopathy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 26, 2026.

The chief scientific officer of the Parkinson’s Foundation discussed how the PD Trial Navigator program helps to identify individuals with Parkinson Disease who may be eligible for the phase 2 NEULARK study. [WATCH TIME: 4 minutes]

The professor of neurology at UT Southwestern Medical Center discussed the Octave Multiple Sclerosis Disease Activity Test as a complementary tool to MRI and clinical assessment in MS. [WATCH TIME: 6 minutes]

A duo of neurologists discussed a new analysis suggesting that gender-affirming hormone therapy was not associated with an increased risk of seizure-related hospitalization among transgender women.

Bevacizumab becomes approved in Japan for neurofibromatosis type 2 following phase 2 data that suggested potential effects on hearing preservation and tumor volume despite the study not meeting its primary efficacy end point.

The associate clinical professor at the University of South Carolina School of Medicine discussed data presented at SLEEP 2026 from a phase 2 study of orexin 2 receptor agonist alixorexton in narcolepsy type 2. [WATCH TIME: 3 minutes]

The FDA has accepted Regeneron Pharmaceuticals’ new drug application of cemdisiran's for generalized myasthenia gravis under priority review, with a target action date of November 2026.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 19, 2026.

The professor of neurology and pediatrics at Vanderbilt University Medical Center discussed her advocacy for sleep health, especially for pediatric patients and their families, at SLEEP 2026. [WATCH TIME: 5 minutes]

The section chief in the Division of Pulmonary Critical Care and Sleep Medicine at West Virginia University discussed new evidence-based guidelines for sleep-disordered breathing in hospitalized patients.

At SLEEP 2026, the section chief in the Division of Pulmonary Critical Care and Sleep Medicine at West Virginia University discussed the high burden of undiagnosed sleep apnea in hospitalized patients. [WATCH TIME: 5 minutes]

Data from phase 3 studies presented at SLEEP 2026 showed that investigational oveporexton was associated with improvements in REM sleep architecture and sleep-related symptoms in patients with NT1.

New phase 2 data showed that riliprubart was associated with sustained improvements in patient-reported outcomes at 76 weeks in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Here's some of what is coming soon to NeurologyLive® this week.

Despite missing its primary end point, the SYNAPSE-CMT trial showed improvements in muscle strength and motor function with ignaseclant treatment in patients with Charcot-Marie-Tooth disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 12, 2026.

Pariceract missed meeting the primary and key secondary efficacy end points in the phase 2b ACTIVATE trial, leading to the discontinuation of its development for GBA1-associated Parkinson disease.